PLoS ONE:血管紧张素II(AngII)促进乳腺癌细胞转移

2012-04-25 Deepblue 生物谷

  乳腺癌是女性排名第一的常见恶性肿瘤,其癌细胞转移是引起患者死亡的主要原因。目前的研究正在进一步阐明癌症转移的限速步骤,比如循环肿瘤细胞的外渗及侵袭。 血管紧张素II是一种主要的血管活性肽,它局部产生并释放到血液。近日,法国巴黎科尚研究所的研究人员着手完成了一项有意义的研究,他们发现血管紧张素II能够促进癌细胞迁移。 在该研究中,他们使用了一个癌症转移的体内模型。为了研究癌细

 

乳腺癌是女性排名第一的常见恶性肿瘤,其癌细胞转移是引起患者死亡的主要原因。目前的研究正在进一步阐明癌症转移的限速步骤,比如循环肿瘤细胞的外渗及侵袭。

血管紧张素II是一种主要的血管活性肽,它局部产生并释放到血液。近日,法国巴黎科尚研究所的研究人员着手完成了一项有意义的研究,他们发现血管紧张素II能够促进癌细胞迁移。

在该研究中,他们使用了一个癌症转移的体内模型。为了研究癌细胞转移的重要步骤,他们将能够稳定产生荧光的乳腺癌细胞系(D3H2LN)注入到裸鼠。通过实时活体影像学研究,他们发现血管紧张素II促进了转移灶的形成。

实验发现,用这种多肽预处理后,发生癌细胞转移的老鼠数量增加,并且每个老鼠体内的转移瘤的数量及大小也相应的增加和增大。在体外,血管紧张素II通过促进癌细胞黏附于内皮细胞、跨内皮迁移并通过细胞外基质,促进了癌症转移。

在分子水平,由DNA微阵列分析表明,血管紧张素II预处理后共有102个基因差异性表达。血管紧张素II调控了两类与其前体血管紧张素原紧密相关的基因。在这些基因中,MMP2/MMP9和ICAM1M的上调表达跟由参与细胞黏附、迁移及侵袭的基因组成的网络相关联。

这些结果表明,靶向血管紧张素II可能会成为抑制浸润性乳腺癌转移的有效策略。相关论文发表在4月20日的PLoS ONE

doi: 10.1371/journal.pone.0035667
PMC:
PMID:

Angiotensin II Facilitates Breast Cancer Cell Migration and Metastasis

Sylvie Rodrigues-Ferreira, Mohamed Abdelkarim, Patricia Dillenburg-Pilla, Anny-Claude Luissint, Anne di-Tommaso, Frédérique Deshayes, Carmen Lucia S. Pontes, Angie Molina, Nicolas Cagnard, Franck Letourneur, Marina Morel, Rosana I. Reis, Dulce E. Casarini, Benoit Terris, Pierre-Olivier Couraud, Claudio M. Costa-Neto, Mélanie Di Benedetto, Clara Nahmias.

Breast cancer metastasis is a leading cause of death by malignancy in women worldwide. Efforts are being made to further characterize the rate-limiting steps of cancer metastasis, i.e. extravasation of circulating tumor cells and colonization of secondary organs.In this study, we investigated whether angiotensin II, a major vasoactive peptide both produced locally and released in the bloodstream, may trigger activating signals that contribute to cancer cell extravasation and metastasis.We used an experimental in vivo model of cancer metastasis in which bioluminescent breast tumor cells (D3H2LN) were injected intra-cardiacally into nude mice in order to recapitulate the late and essential steps of metastatic dissemination. Real-time intravital imaging studies revealed that angiotensin II accelerates the formation of metastatic foci at secondary sites.Pre-treatment of cancer cells with the peptide increases the number of mice with metastases, as well as the number and size of metastases per mouse. In vitro, angiotensin II contributes to each sequential step of cancer metastasis by promoting cancer cell adhesion to endothelial cells, trans-endothelial migration and tumor cell migration across extracellular matrix.At the molecular level, a total of 102 genes differentially expressed following angiotensin II pre-treatment were identified by comparative DNA microarray. Angiotensin II regulates two groups of connected genes related to its precursor angiotensinogen.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1789417, encodeId=8d911e8941758, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri May 11 20:33:00 CST 2012, time=2012-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251881, encodeId=5eda12518814f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455881, encodeId=026d1455881e5, content=<a href='/topic/show?id=2920e8036d8' target=_blank style='color:#2F92EE;'>#细胞转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78036, encryptionId=2920e8036d8, topicName=细胞转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3415750271, createdName=zz72, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506855, encodeId=fd3a1506855cd, content=<a href='/topic/show?id=26cf89e4530' target=_blank style='color:#2F92EE;'>#血管紧张素II#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89745, encryptionId=26cf89e4530, topicName=血管紧张素II)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab559833295, createdName=bbwznl, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589277, encodeId=dd0e15892e7d3, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595890, encodeId=9ffb159589011, content=<a href='/topic/show?id=bdcfe153376' target=_blank style='color:#2F92EE;'>#癌细胞转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71533, encryptionId=bdcfe153376, topicName=癌细胞转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365518309389, createdName=yinhl1984, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1789417, encodeId=8d911e8941758, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri May 11 20:33:00 CST 2012, time=2012-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251881, encodeId=5eda12518814f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455881, encodeId=026d1455881e5, content=<a href='/topic/show?id=2920e8036d8' target=_blank style='color:#2F92EE;'>#细胞转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78036, encryptionId=2920e8036d8, topicName=细胞转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3415750271, createdName=zz72, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506855, encodeId=fd3a1506855cd, content=<a href='/topic/show?id=26cf89e4530' target=_blank style='color:#2F92EE;'>#血管紧张素II#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89745, encryptionId=26cf89e4530, topicName=血管紧张素II)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab559833295, createdName=bbwznl, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589277, encodeId=dd0e15892e7d3, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595890, encodeId=9ffb159589011, content=<a href='/topic/show?id=bdcfe153376' target=_blank style='color:#2F92EE;'>#癌细胞转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71533, encryptionId=bdcfe153376, topicName=癌细胞转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365518309389, createdName=yinhl1984, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-04-27 yxch36
  3. [GetPortalCommentsPageByObjectIdResponse(id=1789417, encodeId=8d911e8941758, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri May 11 20:33:00 CST 2012, time=2012-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251881, encodeId=5eda12518814f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455881, encodeId=026d1455881e5, content=<a href='/topic/show?id=2920e8036d8' target=_blank style='color:#2F92EE;'>#细胞转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78036, encryptionId=2920e8036d8, topicName=细胞转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3415750271, createdName=zz72, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506855, encodeId=fd3a1506855cd, content=<a href='/topic/show?id=26cf89e4530' target=_blank style='color:#2F92EE;'>#血管紧张素II#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89745, encryptionId=26cf89e4530, topicName=血管紧张素II)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab559833295, createdName=bbwznl, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589277, encodeId=dd0e15892e7d3, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595890, encodeId=9ffb159589011, content=<a href='/topic/show?id=bdcfe153376' target=_blank style='color:#2F92EE;'>#癌细胞转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71533, encryptionId=bdcfe153376, topicName=癌细胞转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365518309389, createdName=yinhl1984, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-04-27 zz72
  4. [GetPortalCommentsPageByObjectIdResponse(id=1789417, encodeId=8d911e8941758, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri May 11 20:33:00 CST 2012, time=2012-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251881, encodeId=5eda12518814f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455881, encodeId=026d1455881e5, content=<a href='/topic/show?id=2920e8036d8' target=_blank style='color:#2F92EE;'>#细胞转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78036, encryptionId=2920e8036d8, topicName=细胞转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3415750271, createdName=zz72, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506855, encodeId=fd3a1506855cd, content=<a href='/topic/show?id=26cf89e4530' target=_blank style='color:#2F92EE;'>#血管紧张素II#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89745, encryptionId=26cf89e4530, topicName=血管紧张素II)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab559833295, createdName=bbwznl, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589277, encodeId=dd0e15892e7d3, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595890, encodeId=9ffb159589011, content=<a href='/topic/show?id=bdcfe153376' target=_blank style='color:#2F92EE;'>#癌细胞转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71533, encryptionId=bdcfe153376, topicName=癌细胞转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365518309389, createdName=yinhl1984, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1789417, encodeId=8d911e8941758, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri May 11 20:33:00 CST 2012, time=2012-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251881, encodeId=5eda12518814f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455881, encodeId=026d1455881e5, content=<a href='/topic/show?id=2920e8036d8' target=_blank style='color:#2F92EE;'>#细胞转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78036, encryptionId=2920e8036d8, topicName=细胞转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3415750271, createdName=zz72, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506855, encodeId=fd3a1506855cd, content=<a href='/topic/show?id=26cf89e4530' target=_blank style='color:#2F92EE;'>#血管紧张素II#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89745, encryptionId=26cf89e4530, topicName=血管紧张素II)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab559833295, createdName=bbwznl, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589277, encodeId=dd0e15892e7d3, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595890, encodeId=9ffb159589011, content=<a href='/topic/show?id=bdcfe153376' target=_blank style='color:#2F92EE;'>#癌细胞转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71533, encryptionId=bdcfe153376, topicName=癌细胞转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365518309389, createdName=yinhl1984, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1789417, encodeId=8d911e8941758, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri May 11 20:33:00 CST 2012, time=2012-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251881, encodeId=5eda12518814f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455881, encodeId=026d1455881e5, content=<a href='/topic/show?id=2920e8036d8' target=_blank style='color:#2F92EE;'>#细胞转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78036, encryptionId=2920e8036d8, topicName=细胞转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3415750271, createdName=zz72, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506855, encodeId=fd3a1506855cd, content=<a href='/topic/show?id=26cf89e4530' target=_blank style='color:#2F92EE;'>#血管紧张素II#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89745, encryptionId=26cf89e4530, topicName=血管紧张素II)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab559833295, createdName=bbwznl, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589277, encodeId=dd0e15892e7d3, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595890, encodeId=9ffb159589011, content=<a href='/topic/show?id=bdcfe153376' target=_blank style='color:#2F92EE;'>#癌细胞转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71533, encryptionId=bdcfe153376, topicName=癌细胞转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365518309389, createdName=yinhl1984, createdTime=Fri Apr 27 02:33:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]

相关资讯

EBCC-8:乳腺癌外科治疗进展荟萃

       作者:山东省肿瘤医院乳腺病中心 王永胜        作为两年一次的乳腺癌前沿性学术盛会,第8 届欧洲乳腺癌会议(EBCC-8)致力于呈现乳腺癌领域最新的进展、热点和理念。本次会议的目标包括:(1)关注临床研究向临床实践的快速转化;(2)鼓励乳腺癌各种治疗手段的整合和优化;(3)聚集患者代表、临床医

NICE指南草案不推荐贝伐珠单抗/卡培他滨治疗乳腺癌

       英国临床优化研究所(NICE)日前表示,将不会建议贝伐珠单抗联合卡培他滨治疗进展性转移性乳腺癌。在4月18日发布的新指南草案中,NICE指出,支持这种联合治疗的证据不足。目前已有2种含贝伐珠单抗的方案被欧盟批准作为进展性转移性乳腺癌的一线治疗,本次被NICE否定的方案是其中之一。        

2012 NCCN年会:NCCN肿瘤指南更新要点汇总

       肺癌指南 更新多        今年非小细胞肺癌指南更新颇多,包括对电视胸腔镜手术(VATS)、新药Crizotinib的推荐以及修订腺癌分期等。        分期推荐:EUS/EBUS及原位腺癌       &nb

乳腺癌筛查诊断和治疗进展

       作者:河北省乳腺疾病诊疗中心 河北医科大学第四医院乳腺中心 耿翠芝        化疗        70- 基因检测        荷兰癌症研究所 Linn报告的一项研究对427 例腋淋巴结转移阴性的患

管腔样细胞也能形成较大肿瘤

近期来自哥本哈根大学(CU)和美国劳伦斯伯克力国家实验室的研究人员的一个国际研究研究小组在乳腺癌研究中发现无干细胞特性的管腔样(Luminal-like)细胞也能形成较大的肿瘤,这一研究发现向当前普遍为人们所接受的理念:只有具有干细胞特性的基底样(basal-like)细胞才能形成侵袭性肿瘤提出了挑战。这一研究发现或有可能对于乳腺癌的诊断和治疗以及未来的个体化癌症用药产生重要的影响。相关研究成果发

Breast Cancer Res:蛋白Perp与细胞桥粒或成抑制乳腺癌新靶标

乳腺癌治疗的早期发现和进步能提高患者生存的机会,但是对抗这种疾病的新的治疗途径还需要我们进一步努力。发表在BioMed Central的Breast Cancer Research的杂志上的一项新的研究表明,蛋白PERP与细胞桥粒能抑制乳腺癌,这为今后乳腺癌的治疗提供了潜在的新的靶标。桥粒是相邻细胞间的一种斑点状黏着连接结构。 桥粒连接相邻细胞,这一微小蛋白质的集合调控身体内器官和组织的机械强度